A review of abuse-deterrent opioids for chronic nonmalignant pain

P and T

Volumn 37, Issue 7, 2012, Pages 412-421

  Moorman Li, Robin ^a   Motycka, Carol A ^a   Inge, Lisa D ^a   Congdon, Jocelyn Myrand ^b   Hobson, Susan ^b   Pokropski, Brian ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACURACET; BUPRENORPHINE PLUS NALOXONE; FENTANYL; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; MORPHINE SULFATE PLUS NALTREXONE; NALOXONE PLUS OXYCODONE; NICOTINIC ACID PLUS OXYCODONE; NKTR 181; OPIATE; OXYCODONE; OXYCODONE PLUS PARACETAMOL; OXYMORPHONE; OXYTREX; TAPENTADOL; TAPRENEPAG ISOPROPYL ESTER; UNCLASSIFIED DRUG;

ANALGESIA; AREA UNDER THE CURVE; CHRONIC PAIN; CONTROLLED DRUG RELEASE; DISEASE SEVERITY; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDICATION; DRUG MISUSE; DRUG SAFETY; DRUG STABILITY; HUMAN; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MEDICAL HISTORY; MELTING POINT; OPIATE ADDICTION; PRESCRIPTION; RESPIRATION DEPRESSION; REVIEW; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84865613820     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, D.C.: National Academies of Science; June 29, 2011. Available at: www.iom.edu//media/Files/Report%20Files/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research/Pain%20 Research%202011%20Report%20Brief.pdf. Accessed December 16, 2011.
2. Argoff CE, Albrecht P, Irving G, Rice F. Multimodal analgesia for chronic pain: Rationale and future directions. Pain Med 2009;10(S2):S52-S66.
3. Fine PG, Mahajan G, McPherson ML. Long-acting opioids and short-acting opioids: Appropriate use in chronic pain management. Pain Med 2009;10(S2):S79-S88.
4. Bernstein D, Stowell AW, Haggard R, et al. Complex interplay of participants in opioid therapy. Pract Pain Manage 2007;7:10-36.
5. National Institute on Drug Abuse (NIDA). NIDA Community Drug Alert Bulletin: Prescription Drugs. Bethesda, Md.: U.S. Department of Health and Human Services, 2005. NIH Pub. No. 05-0580. Available at: http://archives.drugabuse.gov/prescripalert/. Accessed November 1, 2011.
6. Passik SD, Kirsh KL, Donaghy KB, Portenoy RK. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 2006;22(2):173-181.
7. Webster LR, Bath B, Medve R.A. Opioid formulations in development designed to curtail abuse: Who is the target? Exp Opin Investig Drugs 2009;18(3):255-263.
8. Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs 2010;70(13):1657-1675.
9. Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009;10(S2):S124-S133.
10. Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007;23(8):648-660.
11. Katz N. Abuse-deterrent opioid formulations: Are they a pipe dream? Curr Rheumatol Rep 2008;10:11-18.
12. Suboxone (buprenorphine and naloxone) Sublingual Tablets, prescribing information. Richmond, Va.: Reckitt Benckiser; December 2011. Available at: www.suboxone.com/pdfs/SuboxonePI_tablet.pdf. Accessed February 3, 2012.
13. Helm S, Trescot A, Colson J, et al. Opioid antagonists, partial agonists, and agonists/antagonists: The role of office-based detoxification. Pain Physician 2008;11:225-235.
14. Orman JS, Keating GM. Buprenorphine/naloxone: A review of its use in the treatment of opioid dependence. Drugs 2009;69(5):577-607.
15. Embeda (morphine sulfate and naltrexone HCl) Extended Release Capsules, prescribing information. Bristol, Tenn.: King Pharmaceuticals, Inc.; July 2010. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=694. Accessed February 3, 2012.
16. Duggan ST, Scott LJ. Morphine/naltrexone. CNS Drugs 2010; 24(6):527-538.
17. Morphine/naltrexone combo temporarily withdrawn. Medscape News. Available at: www.medscape.com/viewarticle/739008. Accessed November 1, 2011.
18. FDA approves tamper-resistant oxymorphone formulation. Medscape News. Available at: www.medscape.com/viewarticle/755260?src=rss. Accessed December 1, 2011.
19. Grünenthal Group. Grünenthal's INTAC technology. Available at: http://grunenthal.com/grt-web/Grunenthal_Group/Research_&_Development/Preclinical_R&D/Novel_drug_delivery_systems/Intac%E2%84%A2_/127701579.jsp;jsessionid=6129785B71A327F8D837E62F62B7B7DE.drp1. Accessed December 1, 2011.
20. Opana ER (oxymorphone HCl) Extended-Release Tablets, prescribing information. Chadds Ford, Pa.: Endo; December 2011. Available at: www.endo.com/pdf/products/Opana%20ER%20PI%2020111212.pdf. Accessed February 3, 2012.
21. Exalgo (hydromorphone HCl) Extended-Release Tablets, prescribing information. Hazelwood, Mo.: Mallinckrodt; November 2010. Available at: www.exalgo.com/media/pdf/exalgo-FullPrescribingInformation.pdf. Accessed December 23, 2011.
22. Carter N, Keating G. OROS hydromorphone prolonged release: A review of its use in the management of chronic, moderate to severe pain. CNS Drugs 2010;24(4):337-361.
23. FDA. Information for healthcare professionals: Hydromorphone hydrochloride extended-release capsules (marketed as Palladone). Available at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm129288.htm. Accessed December 1, 2011.
24. Sathyan G, Xu E, Thipphawong J, Gupta SK. Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. BMC Clin Pharmacol 2007;7(3):1-8.
25. Palangio M, Northfelt DW, Portenoy RK, et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002;23(5):355-368.
26. New OxyContin (oxycodone controlled-release) formulation. Pharmacist Lett Prescriber Lett 2010;26(12):261201.
27. Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: What is their role in addressing prescription opioid abuse? CNS Drugs 2010; 24(10):805-810.
28. Oxycontin (oxycodone HCl) Controlled-Release Tablets, prescribing information. Stamford, Conn.: Purdue Pharma LP; November 2007. Available at: www.accessdata.fda.gov/drug-satfda_docs/label/2009/020553s060lbl.pdf. Accessed January 1, 2012.
29. Fiore K. FDA okays new abuse-resistant opioid. MedPage Today, June 20, 2011. Available at: www.medpagetoday.com/ProductAlert/Prescriptions/27157. Accessed December 23 2011.
30. FDA approves tamper-resistant oxycodone. Medscape Medical News, WebMD; June 20, 2011. Available at: www.medscape.com/viewarticle/744935. Accessed December 23, 2011.
31. Aversion technology. Acura. Available at: http://acurapharm.com/research-development/aversion-technology. Accessed December 23, 2011.
32. Oxecta Tablets. Available at: http://acurapharm.com/products/acurox-without-niacin-tablets. Accessed December 23, 2011.
33. Adams B. FDA approves Pfizer pain drug Oxecta. InPharm, June 21, 2011. Available at: www.inpharm.com/news/160392/fda-approves-pfizer-pain-drug-oxecta. Accessed December 14, 2011.
34. Oxecta (oxycodone HCl, USP) Tablets, prescribing information. Bristol, Tenn.: King Pharmaceuticals, Inc.; June 2011. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=620. Accessed December 23, 2011.
35. Acuracet tablets. Acura. Available at: http://acurapharm.com/products/acuracet-tablets. Accessed December 23, 2011.
36. Vycavert tablets. Acura. Available at: http://acurapharm.com/products/vycavert-tablets. Accessed December 23, 2011.
37. Largent-Milnes TM, Guo W, Wang HY, et al. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling. J Pain 2008; 9(8):700-713.
38. Webster LR. Oxytrex: An oxycodone and ultra-low-dose naltrexone formulation. Exp Opin Investig Drugs 2007;16(8):1277-1283.
39. Webster LR, Butera PG, Moran LV, et al. Oxytrex minimizes physical dependence while providing effective analgesia: A randomized controlled trial in low back pain. J Pain 2006; 7 (12):937-946.
40. Collegium Pharmaceutical. Technology introduction. Available at: www.collegiumpharma.com/technology-introduction. Accessed December 13, 2011.
41. Collegium Pharmaceutical. DETERx formulation design. Available at: www.collegiumpharma.com/deterxatrade-formulation-design. Accessed December 13, 2011.
42. Collegium Pharmaceutical. DETERx tamper resistance. Available at: www.collegiumpharma.com/deterx-tamper-resistance. Accessed December 13, 2011.
43. Collegium Pharmaceutical, Inc., announces successful type A meeting with FDA for tamper-resistant, extended-release opioid. Business Week, September 26, 2011. Available at: http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=7490189. Accessed December 23, 2011.
44. Collegium Pharmaceutical. Products/pipeline. Available at: www.collegiumpharma.com/productspipeline. Accessed December 23, 2011.
45. Nektar Therapeutics, Product Fact Sheet, 2011. CNS/PAIN-NKTR-181: New mu-opioid analgesic with novel molecular structure in clinical development as a safer, abuse-deterrent pain therapeutic. Available at: www.nektar.com/pdf/pipeline/NKTR-181/product_fact_sheet.pdf. Accessed December 13, 2011.
46. Nektar announces positive clinical data from second phase 1 clinical study of NKTR-181, a novel opioid analgesic molecule to treat chronic pain. Daily Markets December 13, 2011. Available at: www.dailymarkets.com/stock/2011/12/13/nektar-announces-positive-clinical-data-from-second-phase-1-clinical-study-of-nktr-181-a-novel-opioid-analgesic-molecule-to-treat-chronic-pain. Accessed December 13, 2011.
47. Nektar/PR Newswire. Nektar announces that FDA grants fast track designation to NKTR-181, a new oral opioid analgesic molecule for the treatment of moderate-to-severe chronic pain, June 7, 2012. Available at: http://ir.nektar.com/releasedetail.cfm?ReleaseId=681109. Accessed June 18, 2012.
48. Pharmaco Fore. Pipeline: Moderateto severe pain. Available at: www.pharmacofore.com/view.cfm/39/Moderate-to-Severe-Pain. Accessed December 13, 2011.
49. Fiore K. Companies attempt abuse-proof opioids. MedPage Today, April 13, 2011. Available at: www.medpagetoday.com/Psychiatry/Addictions/25888. Accessed December 13, 2011.
50. PharmacoFore. PharmacoFore, Inc. announces positive results from a phase I clinical study of its hydromorphone Bio-Activated Molecular Delivery™ system and upcoming presentation at the 2011 BIO Business Forum during the annual BIO International Convention in Washington, D.C.; June 23, 2011. Accessed December 14, 2011.
51. Durect Corp. Primary endpoint of pivotal phase III clinical trial achieved for Remoxy, December 6, 2007. Available at: www.durect.com/wt/durect/page_name/pr_1196960615. Accessed December 7, 2011.